Expression of Ki-67, C-erbB2 and EGFR in TCC of the urinary bladder and their correlation with tumor grading

Iranian Red Crescent Medical Journal

Volumn 10, Issue 2, 2008, Pages 95-99

  Shamsdin, Seyedah Azra ^a,b   Mehrabani, D ^b   Hosseinzadeh, M ^a  

^a FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bladder; C erbB2; EGFR; Grading; Ki 67; Transitional cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CORRELATIONAL STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 69749096477     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rosai J, Ackermans R. Surgical pathology. Ninth edition, 2004; 1:1327-37.
2. Kutarski PW, Padwell A. Transitional cell carcinoma of bladder in young adults Br J Urol 1993;72:749-755.
3. Anton-Culver H, Lee-Feldstein A, Taylor TH. Occupation and bladder cancer risk. Am J Epidemiol 1992; 136:89-94.
4. Yurakh AO, Ramos D, Calabuig-Fariñas S, López-Guerrero JA, Rubio J, Solsona E, Romanenko AM, Vozianov AF, Pellin A, Llombart-Bosch A. Molecular and Immunohistochemical analysis of the prognostic value of cell cycle regulators in urothelial neoplasms of bladder. Eur Urol 2006;50(3):506-15.
5. Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R, Lopez-Beltran A. Ki-67 MIB1 labelling index and the prognosis of primaring TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006; 59(1):83-88.
6. Santos LL, Amaro T, Pereira SA. Expression of cell cycle regulatory proteins and their prognostic value in superficial low grade urothelial cell carcinoma of bladder. Eur J Surg Oncol 2003; 29(1):74-80.
7. Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I. Current concepts in biomarker technology for bladder cancers. Clinical Chemistry 2000; 46(5):595-605.
8. Okamura K, Miyake K, Koshikawa T, Asai J. Growth fractions oftransitional cell carcinomas of the bladder defined by the monoclonal antibody ki-67. J Urol 1990;144:875-8.
9. Wells A. Molecues in focus: EGFR receptor. Int J Biochem Cell Biol 1999;31:637-643.
10. Gorgoulis VG, Barbatis C, Poulias I, Karameris AM. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and cerb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod Pathol 1995; 8(7):758-64.
11. Moreno Sierra J, Maestro de las Casas ML, Chicharro Almarza J, Ortega Heredia MD, López García-Asenjo J, Merino Sánchez C, Blanco Jiménez E, Silmi Moyano A, Rsesel Estévez L. The molecular biology of bladder carcinoma. Arch Esp Urol 1997; 50(8):855-66.
12. Fradet Y, Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Semin Urol 1993; 11:145-53.
13. Cordon-Cardo C. Mutation of cell cycle regulators:biological and clinical implications for human neoplasia. Am J Pathol 1995; 147:545-560.
14. Reznikoff CA, Belair CD, Yeager TR, Savelieva E, Blelloch RH, Puthenveettil JA, Cuthill S. A molecular genetic model of human bladder cancer pathogenesis. Semin Oncol 1996;23:571-584.
15. Bol MG, Baak JP, van Diermen B, Buhr-Wildhagen S, Janssen EA, Kjellevold KH, Kruse AJ, Mestad O, Øgreid P. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. J Clin Pathol 2003;56:447-52.
16. Dybowski B, Kupryjanczyk J, Rembiszewska A, Pykalo R, Borkowski A. P27kip1 ki-67 expression analysis in transitional cell carcinoma of the bladder. Urol Res 2003;31:397-401.
17. Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S. Prognostic value o9f ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997;79:367-372.
18. Okamura K, Miyake K, Koshikawa T, Asai J. Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody ki-67. J Urol 1990;144:875-878.
19. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Comino A, Navone R. Proliferative activity is the most significant predictor of recurrence in non-invasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder. Cancer 2002;15:784-90.
20. Yan Y, Andriole GL, Humphrey PA, Kibel AS. Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. Cancer 2002;95:1239-46.
21. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-21
22. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Can Res 2002;8:3438-3444.
23. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor a in the progression of prostatic neoplasms. Clin Cancer Res 1995; 1:545-550.
24. Popov Z, Gil-Diez-De-Medina S, Ravery V, Hoznek A, Bastuji-Garin S, Lefrere-Belda MA, Abbou CC, Chopin DK. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 2004;22(2):93-101.
25. Tannapfel A, Kühn R, Kessler H, Wittekind C. Expression of c-erbB2 oncogene product in different tumours and its standardised evaluation. Anal Cell Pathol 1996;10(2):149-60.
26. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5(12):4079-84.